<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372382">
  <stage>Registered</stage>
  <submitdate>19/02/2017</submitdate>
  <approvaldate>23/02/2017</approvaldate>
  <actrnumber>ACTRN12617000282381p</actrnumber>
  <trial_identification>
    <studytitle>Vitamin K2 Supplementation in Haemodialysis</studytitle>
    <scientifictitle>An open-label, feasibility study of Menaquinone-7 enriched supplement in haemodialysis patients.</scientifictitle>
    <utrn>U1111-1193-2174</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End Stage Kidney Disease</healthcondition>
    <healthcondition>Vascular calcification</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The product is milk enriched with Menaquinone-7. 
The subject will be administered  Menaquinone-7 1ug in 200ml. of milk.. 
Administered 3 times a week on dialysis for 8 weeks. 
Patients will be administered the treatment while at dialysis so will be directly observed.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The tolerability of a novel functional health product enriched in MK-7 assessed by study dieticians. The product will either be classified as "Yes" tolerable or "No" not tolerable.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Markers of Vitamin K deficiency will be assessed by obtaining blood samples at baseline, 8 weeks of treatment and 12 weeks (four weeks after halting treatment). Serum will be assessed for concentrations of::
Circulating dephosphorylated-uncarboxylated-matrix Gla protein, 
Uncarboxylated osteocalcin and 
Protein induced in vitamin K absence II</outcome>
      <timepoint>Baseline
8 weeks
12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>5 point Likert scale to assess acceptability of the MK-7 enriched product </outcome>
      <timepoint>Weekly for 8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ESRD established for more than 6 months on centre or satellite haemodialysis, 
Stable medical condition, 
Over the age of 18 years
Are able to provide informed consent will be eligible to participate. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Therapy with warfarin, 
Life expectancy of less than 6 month, 
Planned renal transplantation within 3 months, 
Intestinal malabsorption or significant gastrointestinal disease, 
Inability to provide informed consent.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Not applicable</concealment>
    <sequence>Not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>nonparametric Kruskal-Wallis and Mann-Whitney test</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/12/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Waitemata District Health Board</primarysponsorname>
    <primarysponsoraddress>Waitemata DHB, 
Private Bag 93503, 
Takapuna, 
Auckland 0740
New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>To be obtained</fundingname>
      <fundingaddress>Not applicable</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Waikato </othercollaboratorname>
      <othercollaboratoraddress>School of Engineering
Private Bag 3105
Waikato 3240
</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Kidney disease is a major public health issue. The provision of dialysis has considerable economic impact; $150 million, 0.9% of the annual health budget is spent on treatment of End Stage Kidney Disease (ESKD) for &lt;0.09% of the NZ population. There has been a steady growth in the number of patients with ESRD of 5-6% over the last 15 years. Cardiovascular disease is the major cause of mortality and a significant cause of morbidity in this group. 

Menaquinone-7, a Vitamin K2 homologue is rare in the Western diet, has high potency, and a long half-life and may reduce cardiovascular disease.

We will trial if a  novel health product enriched in Menaquinone-7, is tolerated in up to 30 patients with ESRD. 

We will determine if the novel health product enriched in Menaquinone-7, will reverse markers of Vitamin K deficiency.

</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Health and Disability Ethics Committees
PO Box 5013
Wellington 6140</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/06/2017</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Janak de Zoysa</name>
      <address>North Shore Hospital, 
Private Bag 93503, 
Takapuna, 
Auckland 0740
New Zealand</address>
      <phone>+6494868900</phone>
      <fax />
      <email>janak.dezoysa@waitematadhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Aydin Berenjian</name>
      <address>School of Engineering, 
University of Waikato
Private Bag 3105
Hamilton 3240</address>
      <phone>+64 7 858 5119</phone>
      <fax />
      <email>aydin.berenjian@waikato.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Aydin Berenjian</name>
      <address>School of Engineering, 
University of Waikato
Private Bag 3105
Hamilton 3240</address>
      <phone>+64 7 858 5119</phone>
      <fax />
      <email>aydin.berenjian@waikato.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>